1,928 results on '"WALDENSTROM'S macroglobulinemia"'
Search Results
2. A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
- Author
-
Bristol-Myers Squibb and Steven Treon, MD, PhD, MD, PhD
- Published
- 2024
3. Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
- Author
-
Millennium Pharmaceuticals, Inc.
- Published
- 2024
4. Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
- Author
-
Irene Ghobrial, MD, Principal Investigator
- Published
- 2024
5. Antineutrophil cytoplasmic antibody‐negative pauci‐immune glomerulonephritis in a patient with Waldenstrom macroglobulinaemia.
- Author
-
Au‐Yang, Wai, Cheung, Tai Yiu, Chan, Hui Yiu, Cheuk, Wah, and Cheung, Chi Yuen
- Subjects
- *
ANTINEUTROPHIL cytoplasmic antibodies , *WALDENSTROM'S macroglobulinemia , *ACUTE kidney failure , *CHRONIC leukemia ,BONE marrow examination - Abstract
Waldenstrom macroglobulinaemia (WM), the predominant subtype of lymphoplasmacytic lymphoma with bone marrow involvement and serum IgM paraprotein, is a haematological condition commonly associated with renal parenchymal involvement. However, antineutrophil cytoplasmic antibody (ANCA)‐negative pauci‐immune crescentic glomerulonephritis (PICGN) in kidney infiltrated by lymphoma is very rare, with only two cases described in chronic lymphocytic leukaemia in English literature so far. We herein report the first patient with WM developing ANCA‐negative PICGN. He was a 76‐year‐old male who presented with elevated serum globulin level and bilateral groin lymph node enlargement, subsequently diagnosed to have WM after pathologic examination of the bone marrow and groin lymph node. One month later, he was found to have acute kidney injury and proteinuria. Renal biopsy confirmed the presence of parenchymal involvement by WM accompanied by PICGN; while ANCA testing was negative. He was treated with pulse methylprednisolone followed by oral prednisolone. In addition, six courses of intravenous rituximab and oral cyclophosphamide were given. There was significant improvement in both his renal and haematological conditions. The clinical course of this case suggested that ANCA‐negative PICGN may represent a paraneoplastic syndrome and a rare manifestation of WM‐associated renal lesion. Early kidney biopsy and prompt treatment may improve the outcome of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial.
- Author
-
Szymura, Szymon J., Wang, Lin, Zhang, Tiantian, Cha, Soung-chul, Song, Joo, Dong, Zhenyuan, Anderson, Aaron, Oh, Elizabeth, Lee, Vincent, Wang, Zhe, Parshottam, Sapna, Rao, Sheetal, Olsem, Jasper B., Crumpton, Brandon N., Lee, Hans C., Manasanch, Elisabet E., Neelapu, Sattva, Kwak, Larry W., and Thomas, Sheeba K.
- Subjects
B cell receptors ,WALDENSTROM'S macroglobulinemia ,SOMATOMEDIN ,MYELOID cells ,PLASMA cells ,B cells - Abstract
Lymphoplasmacytic lymphoma (LPL) is an incurable low-grade lymphoma with no standard therapy. Nine asymptomatic patients treated with a first-in-human, neoantigen DNA vaccine experienced no dose limiting toxicities (primary endpoint, NCT01209871). All patients achieve stable disease or better, with one minor response, and median time to progression of 72+ months. Post-vaccine single-cell transcriptomics reveal dichotomous antitumor responses, with reduced tumor B-cells (tracked by unique B cell receptor) and their survival pathways, but no change in clonal plasma cells. Downregulation of human leukocyte antigen (HLA) class II molecules and paradoxical upregulation of insulin-like growth factor (IGF) by the latter suggest resistance mechanisms. Vaccine therapy activates and expands bone marrow T-cell clonotypes, and functional neoantigen-specific responses (secondary endpoint), but not co-inhibitory pathways or Treg, and reduces protumoral signaling by myeloid cells, suggesting favorable perturbation of the tumor immune microenvironment. Future strategies may require combinations of vaccines with agents targeting plasma cell subpopulations, or blockade of IGF-1 signaling or myeloid cell checkpoints. Lymphoplasmacytic lymphoma is a B-cell low-grade lymphoma with no approved standard therapy. Here the authors report a non-randomized phase 1 clinical trial performing early intervention with personalized neoantigen vaccines in asymptomatic patients and associating clinical efficacy with successful perturbation of the tumor immune microenvironment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Pharmaceutical Fermentation: Antibiotic Production and Processing.
- Author
-
Zhgun, Alexander A.
- Subjects
ORNITHINE decarboxylase ,MANUFACTURING processes ,FERMENTATION ,ANTIBIOTICS ,CEPHALOSPORINS ,HAIRY cell leukemia ,WALDENSTROM'S macroglobulinemia ,BETA lactam antibiotics - Abstract
The article highlights the transformative impact of antibiotics introduced in the mid-20th century. Topics include the exploration of secondary metabolites from microorganisms as potential new antimicrobial drugs, the three approaches to antibiotic production—fermentation, semi-synthetic modification, and chemical synthesis—and a study on the metabolic potential of Arctic fungi, which revealed novel secondary metabolites and biosynthetic gene clusters.
- Published
- 2024
- Full Text
- View/download PDF
8. Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review.
- Author
-
Itchaki, Gilad, Jarhovsky, Osnat, Castillo, Jorge J., Hassan, Hamza, Gatt, Moshe L., Leiba, Merav, Raanani, Pia, Gertz, Morie A., and Vaxman, Iuliana
- Subjects
- *
LITERATURE reviews , *MULTIPLE myeloma , *WALDENSTROM'S macroglobulinemia , *PLASMA cells ,ISRAEL-United States relations - Abstract
The simultaneous occurrence of Waldenström macroglobulinemia and multiple myeloma in the same patient has been published as case reports. Patients with Waldenström macroglobulinemia often have a small clone of plasma cells. However, the concurrent occurrence of symptomatic myeloma with lytic bone lesions is rare. The diagnosis of this 'hybrid' entity is challenging, and there are no standard therapies. We present six patients from five centers (three in Israel and two in the United States). We describe these patients' unique clinical course and treatment approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Infection as a trigger of acute, transient glomerular deposition of clonal immunoglobulins.
- Author
-
Wang, Bangchen, Schub, Micah, Robinson, Derrick L., and Howell, David N.
- Subjects
- *
PLASMA cells , *IMMUNOGLOBULIN M , *IMMUNOGLOBULINS , *ACUTE kidney failure , *WALDENSTROM'S macroglobulinemia , *INFECTION - Abstract
Glomerular deposition of monoclonal IgM, frequently in the form of intracapillary pseudothrombi, can be seen in Waldenström macroglobulinemia (WM) and type I cryoglobulinemia (CG). They are typically associated with plasma cell or B-lymphoid neoplasms, particularly lymphoplasmacytic lymphoma (LPL). While infection is a frequent trigger of mixed (type II and III) CG, its association with type I CG is uncommon. We report two cases in which striking lambda-chain-restricted IgM deposits and acute kidney injury (AKI) occurred in the setting of known or suspected systemic infections, with prompt resolution on treatment of the infection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia.
- Author
-
Izutsu, Koji, Kato, Hisashi, Sekiguchi, Naohiro, Fujisaki, Tomoaki, Kawakita, Toshiro, Obara, Naoshi, Matsue, Kosei, Nishimoto, Mitsutaka, Hatayama, Tomoyoshi, Inagaki, Mitsuo, and Fujikawa, Ei
- Abstract
Ibrutinib is a first-in-class Bruton kinase inhibitor against B-cell neoplasms including Waldenström macroglobulinemia (WM). This study evaluated the efficacy and safety of ibrutinib-rituximab in Japanese patients with WM. Patients received ibrutinib 420 mg orally once daily plus weekly rituximab 375 mg/m
2 IV (8 infusions total). The primary end point was major response rate (MRR; PR or better) by Independent Review Committee assessment. Secondary endpoints were progression-free survival (PFS), safety, pharmacokinetics, and biomarkers. Primary analysis was conducted in 16 patients [baseline, treatment naïve: 8 (50.0%); relapsed/refractory WM: 8 (50.0%)] who received ibrutinib-rituximab, after all patients completed Week 57 or end of treatment. At primary analysis, MRR was 87.5% [14/16 patients; 95% CI: 61.7, 98.4%; p < 0.0001 (null hypothesis: 32% response rate)]. At final analysis (median study intervention duration: 34.4 months, median follow-up: 35.0 months), MRR was unchanged at 87.5%, but VGPR [6/16 (37.5%)] and PR [8/16 (50.0%)] improved. Prior treatment status did not affect response. At final analysis, median PFS was not reached [36-month PFS rate: 86% (95% CI: 55, 96%)]. No critical safety signals were reported. This study demonstrated a positive benefit/risk profile of ibrutinib-rituximab in Japanese patients with WM, consistent with the iNNOVATE study. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
11. Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma (ARIADNE)
- Author
-
BeiGene Switzerland GmbH
- Published
- 2023
12. R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia (Ballondor)
- Author
-
Ho Sup Lee, MD, PhD. associate professor.
- Published
- 2023
13. Sudden unexpected death after initial infusion of rituximab for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma: an autopsy case.
- Author
-
Ichimata, Shojiro, Hata, Yukiko, Nomoto, Kazuhiro, Sato, Tsutomu, and Nishida, Naoki
- Subjects
- *
AUTOPSY , *RITUXIMAB , *WALDENSTROM'S macroglobulinemia , *SUDDEN death , *BONE marrow cells , *OLDER men , *IMMUNOGLOBULIN light chains - Abstract
Background: Waldenström's macroglobulinemia (WM) is defined as a lymphoplasmacytic lymphoma (LPL) involving the bone marrow (BM) with presence of IgM monoclonal protein, and comprises > 95% of all LPL cases. Rituximab-based regimens have been predominant in the management of WM. Infusion-related reactions (IRRs) are a primary concern with rituximab, although it is generally better tolerated with less toxicity than conventional anticancer agents. Here, we present an autopsy case of an elderly man who died suddenly after receiving the initial infusion of rituximab for WM/LPL. Case presentation: An 84-year-old man was found dead in his bedroom. He had undergone the initial intravenous rituximab infusion for progressive anemia related to Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) approximately 15 h before death. Although the protocol for rituximab administration and additional medication was considered appropriate, he exhibited several symptoms consistent with infusion-related reactions (IRRs) during the infusion. Autopsy revealed monotonous proliferation of small-to-medium-sized lymphocytic cells in the bone marrow, consistent with the premortem diagnosis of WM/LPL. Additionally, immunoglobulin λ-light chain-derived amyloid (ALλ) deposition was identified in all organs other than the brain. Although ALλ deposition and LPL infiltration were found in the heart, they were not severe enough to cause severe functional impairment. Severe congestion and/or edema were observed in the lungs, liver, and brain. Although significant inflammatory cell infiltration was not found in any organs, laboratory tests revealed elevated serum levels of inflammatory cytokines, including interleukin-1β, interleukin-6, tumor necrosis factor-α and the presence of IgM-λ monoclonal protein. Conclusion: Acute IRRs associated with the initial rituximab infusion were the major contributing factor to his sudden unexpected death. The autopsy findings of present case suggest the necessity for thorough monitoring of older patients with WM/LPL undergoing rituximab treatment, particularly when pronounced IRRs occur during the first administration, in addition to investigating complications of WM/LPL before infusion. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Waldenstrom Macroglobulinemia Recurrence with Bing–Neel Syndrome Presentation.
- Author
-
Capasso, Raffaella, Buonincontro, Miriam, Caranci, Ferdinando, and Pinto, Antonio
- Subjects
- *
WALDENSTROM'S macroglobulinemia , *MONOCLONAL gammopathies , *CENTRAL nervous system , *SUBARACHNOID space , *SPINAL cord , *CEREBROSPINAL fluid - Abstract
Bing–Neel syndrome (BNS) is a rare condition that may occur in patients with Waldenstrom macroglobulinemia (WM) and is caused by lymphoplasmacytic infiltration into the central nervous system. BNS is an extramedullary manifestation of WM which may present with various neurological signs and symptoms that make the diagnosis difficult to achieve. We present a case of BNS in a 60-year-old patient diagnosed 6 years after recovering from Waldenstrom's macroglobulinemia. We observed the patient for a secondary generalized focal motor seizure. Unenhanced brain CT revealed slight hyperdensity of left parietal subarachnoid spaces. The MRI of the brain and spinal cord showed leptomeningeal enhancement in both parietal lobes. The presence of monoclonal bands (light chain k and IgM) was found in cerebrospinal fluid, leading to the diagnosis of BNS. The patient started treatment with ibrutinib and remains clinically stable during a 1-year follow-up. However, the MRI showed the appearance of a new subcortical left parietal lesion. BNS is an extremely rare presentation of WM that should be recognized and considered early in the presence of unexplained neurological symptoms in patients with a history of WM, even if the patient appears to have recovered. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice.
- Author
-
Østergaard, Simon, Schejbel, Lone, Breinholt, Marie Fredslund, Pedersen, Mette Ølgod, Hammer, Troels, Munksgaard, Lars, Nørgaard, Peter, Høgdall, Estrid, Gjerdrum, Lise Mette Rahbek, and Nielsen, Torsten Holm
- Subjects
- *
NUCLEOTIDE sequencing , *SOMATIC mutation , *LYMPHOMAS , *PHENOTYPES , *GENETIC mutation , *WALDENSTROM'S macroglobulinemia - Abstract
Next-generation sequencing (NGS) affords comprehensive insights into the genomic landscape of lymphomas. We examined the mutational pattern in patients with Waldenström macroglobulinemia (WM) or lymphoplasmacytic lymphoma (LPL) as well as the diagnostic and clinical utility of a tailored NGS lymphoma panel. A consecutive series of 45 patients was reviewed and NGS analysis was performed as part of a routine diagnostic setup. The custom designed NGS panel assayed all coding sequences of 59 genes of known clinical significance in lymphoid neoplasms. The most frequently mutated genes were MYD88, CXCR4, BIRC3, CD79B, and ARID1A. Additional somatic mutations were detected in 17 genes with four mutations categorized as pathogenic or likely pathogenic. BIRC3 and TP53 mutations were associated with adverse clinical phenotypes. NGS performance for the MYD88L265P variant was 96% when compared to qPCR. In conclusion, targeted NGS provided important diagnostic and prognostic information in a routine clinical setting. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Bing–Neel syndrome, a rare manifestation of WM; a case report and review of literature.
- Author
-
Rezvani, Hamid, Salari, Sina, Borhani, Hamed, Mataji, Maedeh, and Azhdari Tehrani, Hamed
- Subjects
- *
LITERATURE reviews , *WALDENSTROM'S macroglobulinemia , *SYMPTOMS , *SYNDROMES , *POLYNEUROPATHIES - Abstract
Key Clinical Message: Bing–Neel syndrome (BNS) is a rare manifestation in individuals suffering from Waldenström macroglobulinemia (WM). Neurological signs and symptoms in this syndrome are almost difficult to be differentiated from other common neurological manifestations of hyper‐viscosity or Waldenström‐associated polyneuropathy. In this paper, we report a new case of WM with concurrent BNS, then review the clinical picture and treatment of this syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome.
- Author
-
Ito, Kenichi, Kawasaki, Tomoki, Hirano, Kazuhiko, and Sekiguchi, Naohiro
- Subjects
PLASMAPHERESIS ,WALDENSTROM'S macroglobulinemia ,IMMUNOGLOBULIN M ,SYNDROMES ,VON Willebrand disease - Abstract
Introduction: Hyperviscosity syndrome (HVS) is a significant complication in Waldenström's macroglobulinemia (WM), although the significance of plasmapheresis in clinical practice has not been clarified. To confirm the efficacy and safety of plasmapheresis followed by primary therapy for WM with HVS, we retrospectively conducted this study. Methods: Untreated WM with HVS, or serum immunoglobulin M (IgM) levels ≥4000 mg/dL, were analyzed. The basic therapeutic flow was conducted as follows: (1) performing plasmapheresis, (2) followed by primary therapy without rituximab, and (3) performing the second cycle. The serum IgM reduction rate and adverse events (AEs) were evaluated. Results: Ten patients were enrolled. The median serum IgM levels at diagnosis, post‐plasmapheresis, after the first cycle of primary therapy, and after the second cycle were 5174, 2900, 3286, and 2657 mg/dL, respectively. No patients experienced IgM flare or bleeding AEs. Conclusion: The therapeutic flow offers sufficient efficacy and safety in WM with HVS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases.
- Author
-
Zhang, Li-Fen, Zhang, Yan, Shui, Rou-Hong, Lu, Hong-Fen, Jiang, Wen-Hua, Cai, Xu, Li, Xiao-Qiu, and Yu, Bao-Hua
- Subjects
- *
B cells , *DIFFUSE large B-cell lymphomas , *WALDENSTROM'S macroglobulinemia , *MANTLE cell lymphoma , *MYC oncogenes , *LYMPHOMAS , *MUCOSA-associated lymphoid tissue lymphoma - Abstract
Aims: MNDA (myeloid nuclear differentiation antigen) has been considered as a potential diagnostic marker for marginal zone lymphoma (MZL), but its utility in distinguishing MZL from other B-cell non-Hodgkin lymphomas (B-NHLs) and its clinicopathologic relevance in diffuse large B-cell lymphoma (DLBCL) are ambiguous. We comprehensively investigated MNDA expression in a large series of B-NHLs and evaluated its diagnostic value. Methods: MNDA expression in a cohort of 1293 cases of B-NHLs and 338 cases of reactive lymphoid hyperplasia (RLH) was determined using immunohistochemistry and compared among different types of B-NHL. The clinicopathologic relevance of MNDA in DLBCL was investigated. Results: MNDA was highly expressed in MZLs (437/663, 65.9%), compared with the confined staining in marginal zone B-cells in RLH; whereas neoplastic cells with plasmacytic differentiation lost MNDA expression. MNDA expression was significantly higher in mantle cell lymphoma (MCL, 79.6%, p = 0.006), whereas lower in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL, 44.8%, p = 0.001) and lymphoplasmacytic lymphoma (LPL, 25%, p = 0.016), and dramatically lower in follicular lymphoma (FL, 5.2%, p < 0.001), compared with MZL. 29.6% (63/213) of DLBCLs were positive for MNDA. The cases in non-GCB group exhibited a higher rate of MNDA positivity (39.8%) compared to those in GCB group (16.3%) (p < 0.001), and MNDA staining was more frequently observed in DLBCLs with BCL2/MYC double-expression (50%) than those without BCL2/MYC double-expression (24.8%) (p = 0.001). Furthermore, there was a significant correlation between MNDA and CD5 expression in DLBCL (p = 0.036). Conclusions: MNDA was highly expressed in MZL with a potential utility in differential diagnosis between MZL and RLH as well as FL, whereas its value in distinguishing MZL from MCL, CLL/SLL is limited. In addition, MNDA expression in DLBCL was more frequently seen in the non-GCB group and the BCL2/MYC double-expression group, and demonstrated a correlation with CD5, which deserves further investigation. The clinical relevance of MNDA and its correlation with the prognosis of these lymphomas also warrant to be fully elucidated. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Early progression is associated with worse survival in patients with Waldenström's macroglobulinemia.
- Author
-
Xiong, Wenjie, Wang, Zanzan, Wang, Huihan, Li, Chunrui, Chu, Xiaoxia, Li, Bingzong, Yu, Ying, Sun, Hao, Cao, Xinxin, Jiang, Zhongxing, Yang, Guangzhong, Song, Jia, Cai, Zhen, Du, Juan, Sun, Chunyan, Niu, Ting, Wei, Yongqiang, Xue, Hua, Huang, Honghui, and Li, Zhenling
- Subjects
RESEARCH funding ,DESCRIPTIVE statistics ,CHI-squared test ,MANN Whitney U Test ,KAPLAN-Meier estimator ,LYMPHOPROLIFERATIVE disorders ,CONFIDENCE intervals ,DATA analysis software ,DISEASE progression ,OVERALL survival - Abstract
Early progression of disease within 24 months (POD24) of diagnosis is associated with inferior overall survival (OS) in follicular lymphoma, but its prognostic role in Waldenström's macroglobulinemia (WM) is still unclear. Here, we performed a retrospective analysis of 373 patients pooled from the database of the Chinese Registration Network for WM (CRNWM) to determine the outcomes of early progressors. POD24 occurred in 98 evaluable patients (26.3%). The median OS in patients with POD24 was 40 months (95%CI: 15.2–64.0), which was significantly shorter than that without POD24 (156 months, 95%CI: 123.6–188.4; HR: 6.587, 95% CI 4.392–9.881, P < 0.0001). Moreover, subgroup analysis showed that POD24 still maintained its predictive ability of inferior OS in patients treated with rituximab or bortezomib-based treatment. Patients with a very high-risk rIPSSWM stage were more likely to have POD24 (P = 0.020). In conclusion, POD24 was associated with poorer survival and may represent a useful endpoint in future prospective clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. C3+ and C3− warm autoimmune hemolytic anemias: A comparison of clinical characteristics and treatment outcomes.
- Author
-
Nunnelee, Jordan, Abeykoon, Jithma Prasad, Ashrani, Aneel A., Elliott, Michelle Ann, Hook, C. Christopher, Pardanani, Animesh, Pruthi, Rajiv K., Rouse, Rachelle L., Sridharan, Meera, Wolanskyj‐Spinner, Alexandra P., and Go, Ronald S.
- Subjects
- *
AUTOIMMUNE hemolytic anemia , *TREATMENT effectiveness , *WALDENSTROM'S macroglobulinemia - Abstract
This article discusses a study that compared the clinical characteristics and treatment outcomes of patients with warm autoimmune hemolytic anemia (WAIHA) who have complement-fixing (C3+) and non-complement fixing (C3-) forms of the disease. The study found that there were no significant differences in demographic composition, clinical findings, or treatment received between the two groups. However, patients in the complement-fixing group had a higher rate and average number of relapse events compared to the non-complement-fixing group. The study suggests that both forms of WAIHA can be approached and treated similarly. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
21. A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia (CZ-WM01)
- Author
-
RenJi Hospital, Huashan Hospital, Shanghai 6th People's Hospital, Huadong Hospital, and Juan Du, Director
- Published
- 2023
22. A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) (ASPEN)
- Published
- 2023
23. Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.
- Author
-
Mouhssine, Samir, Maher, Nawar, Matti, Bassam Francis, Alwan, Alaa Fadhil, and Gaidano, Gianluca
- Subjects
- *
B cells , *B cell lymphoma , *BRUTON tyrosine kinase , *MANTLE cell lymphoma , *B cell receptors , *WALDENSTROM'S macroglobulinemia - Abstract
The B cell receptor (BCR) signaling pathway plays a crucial role in B cell development and contributes to the pathogenesis of B cell neoplasms. In B cell malignancies, the BCR is constitutively active through both ligand-dependent and ligand-independent mechanisms, resulting in continuous Bruton tyrosine kinase (BTK) signaling activation, which provides a survival and proliferation advantage to the neoplastic clone. Among B cell malignancies, those in which the most significant results were obtained by treatment with BTK inhibitors (BTKi) include chronic lymphocytic leukemia, mantle cell lymphoma, lymphoplasmacytic lymphoma, and diffuse large B cell lymphoma. Covalent BTKi (namely ibrutinib, acalabrutinib, and zanubrutinib) functions by irreversibly blocking BTK through covalent binding to the cysteine residue 481 (Cys-481) in the ATP-binding domain. Despite the high efficacy and safety of BTKi treatment, a significant fraction of patients affected by B cell malignancies who are treated with these drugs experience disease relapse. Several mechanisms of resistance to covalent BTKi, including Cys-481 mutations of BTK, have been investigated in B cell malignancies. Non-covalent BTKi, such as pirtobrutinib, have been developed and proven effective in patients carrying both Cys-481-mutated and unmutated BTK. Moreover, targeting BTK with proteolysis-targeting chimeras (PROTACs) represents a promising strategy to overcome resistance to BTKi in B cell neoplasms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. A Rare Case of Non-IgM Lymphoplasmacytic Lymphoma with Unusual Lack of Immunoglobulin Light Chain Production.
- Author
-
Jiejing Yin, Bains, Ashish, Alsammak, Mohamed, and Jian Jeff Fu
- Subjects
- *
IMMUNOGLOBULIN light chains , *PLASMA cells , *BONE marrow , *WEIGHT loss , *BLOOD protein electrophoresis , *WALDENSTROM'S macroglobulinemia , *PLASMACYTOMA - Abstract
Objective: Rare disease. Background: Non-IgM lymphoplasmacytic lymphoma (LPL) is a rare subtype of LPL, constituting less than 5% of the cases, and is often associated with IgG, IgA, or light chain paraproteins and is rarely a non-secretor. Non-IgM LPL remains poorly studied, and the differential diagnosis from other small B-cell lymphomas with plasmacytic differentiation and plasma cell neoplasm is challenging. Case Report: A 67-year-old woman presented with weight loss, persistent anemia, and borderline leukopenia. Serum protein electrophoresis and immunofixation demonstrated a faint IgG and kappa band against a dense polyclonal background. Bone marrow biopsy revealed hypercellular marrow with involvement by abnormal B cells with undetectable surface and cytoplasmic immunoglobulin light chains. Interestingly, these B cells showed no expression of light chains or production of IgG and IgM; however, they showed production of intracytoplasmic IgA. The concomitant neoplastic plasma cells also displayed no definitive light chain expression. Both IgH and IgK gene rearrangements were positive for clonal process. Molecular studies showed positive MYD88 L265P mutation and CXCR4 mutation (c.1013C>G). The overall findings confirmed marrow involvement by non-IgM LPL. The patient received 6 cycles of rituximab and bendamustine treatment, and no residual marrow involvement was found on the follow-up bone marrow biopsy. Conclusions: We report a non-IgM LPL case featuring no light chain production and no heavy chain secretion, which we believe is the first reported case of this kind in the literature. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Sequence-Based Mechanistic Resolution of Amino Acid Replacement and Impact on the Activities of Peptide-Based Derivatives Targeting CXCR4 for the Treatment of Waldenström's Macroglobulinemia.
- Author
-
Elamin, Ghazi, Soremekun, Opeyemi S., Sayed, Shaban R. M., Sidhom, Peter A., Ibrahim, Mahmoud A. A., Ahmed, Muhammad Naeem, and Soliman, Mahmoud E. S.
- Subjects
- *
AMINO acid separation , *CXCR4 receptors , *CHEMOKINE receptors , *AMINO acid sequence , *PEPTIDES , *BLOOD proteins , *AMINO acids , *ARGININE - Abstract
Targeting C-X-C motif chemokine receptor 4 (CXCR4), as an oncogenic factor in Waldenström's Macroglobulinemia (WM), has been considered a promising treatment strategy, and various CXCR4 antagonists, such as small molecules, peptides, and antibodies, are currently in preclinical and clinical phases. Recently, a 16-mer fragment of human serum albumin, the most abundant protein in plasma, has been identified as a potent inhibitor of CXCR4. Hence, it was given the name Endogenous Peptide Inhibitor of CXCR4 (EPI-X4) and demonstrated a less toxic alternative to the current therapies due to its improved selectivity profile. Further research has led to the discovery of optimized EPI-X4 derivatives, JM#21, and WSC02, as potent CXCR4 antagonists. Despite the ongoing research in this area, the molecular basis of how EPI-X4 and its derivatives bind to CXCR4 is still unexplored. In this study, three aspects were investigated using molecular dynamics (MD) simulations and binding energy calculations: (1) mapping the structure-function of the amino acid sequence composition of the peptides to determine the contribution of each amino acid towards the overall binding to CXCR4, as well as the key interaction peptide motifs; (2) the detailed binding mechanism of EPI-X4, JM#21, and WSC02 against CXCR4 at the molecular level; and (3) the impact of peptide binding on the conformational landscape of CXCR4. Per-residue energy decomposition analysis revealed that the inclusion of arginine residue in the peptide sequence has significantly improved the binding affinity towards CXCR4, particularly at positions Arg3 for EPI-X4 and WSC02 and Arg3 and Arg6 for JM#21. This may explain the finding that JM#21 exhibited the highest binding affinity. Additionally, MD simulations coupled with thermodynamic calculations provided a comprehensive picture of the "dynamic" interaction motif of the peptides with CXCR4. Separate MD simulations in a POPC bilayer were executed to determine its effect on the binding energy. This study provides molecular insights into the binding mechanism of the endogenous peptide EPI-X4 and its optimized derivatives with CXCR4, laying the basis for the rational design of optimized peptide derivatives against WM. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer.
- Author
-
Zafeiropoulou, Kalliopi, Kalampounias, Georgios, Alexis, Spyridon, Anastasopoulos, Daniil, Symeonidis, Argiris, and Katsoris, Panagiotis
- Subjects
- *
BORTEZOMIB , *PROTEASOME inhibitors , *WALDENSTROM'S macroglobulinemia , *PROSTATE cancer , *OXIDATIVE stress , *MANTLE cell lymphoma , *AUTOPHAGY - Abstract
Proteasome inhibitors such as Bortezomib represent an established type of targeted treatment for several types of hematological malignancies, including multiple myeloma, Waldenstrom's macroglobulinemia, and mantle cell lymphoma, based on the cancer cell's susceptibility to impairment of the proteasome-ubiquitin system. However, a major problem limiting their efficacy is the emergence of resistance. Their application to solid tumors is currently being studied, while simultaneously, a wide spectrum of hematological cancers, such as Myelodysplastic Syndromes show minimal or no response to Bortezomib treatment. In this study, we utilize the prostate cancer cell line DU-145 to establish a model of Bortezomib resistance, studying the underlying mechanisms. Evaluating the resulting resistant cell line, we observed restoration of proteasome chymotrypsin-like activity, regardless of drug presence, an induction of pro-survival pathways, and the substitution of the Ubiquitin-Proteasome System role in proteostasis by induction of autophagy. Finally, an estimation of the oxidative condition of the cells indicated that the resistant clones reduce the generation of reactive oxygen species induced by Bortezomib to levels even lower than those induced in non-resistant cells. Our findings highlight the role of autophagy and oxidative stress regulation in Bortezomib resistance and elucidate key proteins of signaling pathways as potential pharmaceutical targets, which could increase the efficiency of proteasome-targeting therapies, thus expanding the group of molecular targets for neoplastic disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. A rare case of secondary cutaneous lymphoplasmacytic lymphoma clinically presenting as acquired cutis laxa.
- Author
-
Lim, Dong Jun, Yang, Hee Joo, Lee, Mi Young, Lee, Woo Jin, Won, Chong Hyun, Chang, Sung Eun, and Lee, Mi Woo
- Subjects
- *
WALDENSTROM'S macroglobulinemia , *CUTIS laxa , *EXTRAMEDULLARY diseases , *IMMUNOGLOBULIN heavy chains , *NON-Hodgkin's lymphoma , *AXILLA - Abstract
Lymphoplasmacytic lymphoma (LPL) is a rare variant of non‐Hodgkin lymphoma, accounting for <1% of cases. Skin involvement in LPL is quite rare—accounting for approximately 5% of extramedullary disease—and includes a variety of clinical morphologies, such as erythematous‐to‐violaceous plaques, violaceous nodules or tumors, and ulceration at various anatomical sites. Herein, we report the case of a 45‐year‐old Korean woman who presented with generalized erythematous indurated plaques and pendulous skin growths, which were asymptomatic, with marked diffuse infiltration of lymphocytes and plasma cells in the dermis. Immunohistochemical studies revealed that the lymphoid cells expressed CD3, CD79a, and cytoplasmic IgG, but lacked CD10 and IgM. Moreover, kappa light chain restriction and monoclonal immunoglobulin heavy chain gene rearrangement were observed. Upon further workup, lymphoma involvement was reported in multiple lymph nodes, including those in the cervical and axillary regions. This case shows a unique form of cutaneous LPL clinically presenting as acquired cutis laxa, emphasizing the dermatologists' need to be vigilant for variant forms of this disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Aggressive Lymphoplasmacytic Neoplasm With an Unusual In-frame Deletion of MYD88 Associated With TRAF3 and TP53 Mutations and Complex Karyotype.
- Author
-
Yan, Mingfei, Meyerson, Howard, Oduro, Kwadwo A., Shetty, Shashirekha, and Yoest, Jennifer
- Subjects
- *
B cells , *KARYOTYPES , *MYELOID differentiation factor 88 , *WALDENSTROM'S macroglobulinemia , *MUCOSA-associated lymphoid tissue lymphoma , *GAIN-of-function mutations , *MISSENSE mutation - Abstract
Lymphoplasmacytic lymphoma often needs to be differentiated from other B-cell lymphomas with plasmacytic differentiation, especially marginal zone cell lymphoma. Molecular detection of MYD88 p.L265P hotspot mutation supports the diagnosis of lymphoplasmacytic lymphoma since it is seen in about 90% of such lymphoma, which is much higher than other B-cell lymphomas. MYD88 p.L265P is a gain-of-function mutation that enhances the activity of the NF-κB signaling pathway and therefore drives lymphomagenesis. Other mutations in MYD88 are rarely reported. This study aims to report an unusual MYD88 in-frame deletion in an aggressive lymphoplasmacytic neoplasm. This is an IgM-positive, CD5- and CD10-negative mature B-cell lymphoma with prominent plasmacytic differentiation and aggressive features. The clinical and pathologic findings were most consistent with lymphoplasmacytic lymphoma. Next-generation sequencing identified an unusual MYD88 in-frame deletion in the absence of the hotpot p.L265P mutation. Other concurrent pathogenic mutations also include truncating mutations of TRAF3, which is a negative regulator of the NF-κB signaling pathway, and a missense mutation of TP53. Karyotype analysis showed complex karyotypes, including chromosome 6q deletion. By searching literature and online cancer databases, we identified only 8 other mature B-cell lymphomas with MYD88 in-frame deletions, but none of them was diagnosed with lymphoplasmacytic lymphoma. Recognizing such in-frame deletions is necessary to help understand the mutational spectrum of MYD88 in B-cell lymphomas. It remains to be further investigated whether such MYD88 in-frame deletions are also overrepresented in lymphoplasmacytic lymphoma among other B-cell lymphomas. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation.
- Author
-
Brunner, Andrea, Thalhammer-Thurner, Gudrun Carolina, Willenbacher, Wolfgang, Haun, Margot, Zelger, Bettina Gudrun, and Willenbacher, Ella
- Subjects
- *
LYMPHOMAS , *FRAMESHIFT mutation , *NUCLEOTIDE sequencing , *PROGRESSION-free survival , *BONE marrow , *WALDENSTROM'S macroglobulinemia - Abstract
We performed a molecular analysis of formalin-fixed paraffin embedded and decalcified bone marrow trephine biopsies of 41 patients with a B-cell disorder with lymphoplasmacytic differentiation to enable a more precise diagnosis and to describe potentially prognostic and therapeutic relevant mutations. Analysis was performed with a commercially available next-generation sequencing (NGS) lymphoma panel (Lymphoma Solution, SophiaGenetics). Results were correlated with clinical and pathological parameters. Our group covered a spectrum of B-cell disorders with plasmacytic differentiation ranging from Waldenstroem's macroglobulinemia (WM), to small-B-cell lymphomas with plasmacytic differentiation (SBCL-PC) to IgM myeloma (MM). The most helpful diagnostic criteria included morphology and immuno-phenotype as a prerequisite for the interpretation of molecular analysis. MYD88 mutation was present in nearly all WM, but also in 50% of SBCL-PCs, while MM were consistently negative. Driver mutations, such as TP53, were already detectable early in the course of the respective diseases indicating a higher risk of progression, transformation, and reduced progression-free survival. In addition, we report on a novel BIRC3 frameshift mutation in one case of a progressive WM. Our data indicate that patients with LPL/WM might benefit from thorough pathological work-up and detailed molecular analysis in terms of precise diagnosis and targeted treatment allocation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenström's Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study.
- Author
-
Yi, Shuhua, Cai, Zhen, Hu, Yu, He, Aili, Gao, Sujun, Li, Qian, Sha, Linlin, Zhang, Nating, Ren, Yupeng, Gai, Xue, Yang, Xue, Qin, Rui, and Qiu, Lugui
- Abstract
Introduction: Waldenström's macroglobulinemia (WM) is a rare malignant B cell lymphoma which occurs in around 1–2% of all hematologic tumors. Ibrutinib was approved in China for WM on the basis of two global pivotal studies which enrolled no Chinese patients. The aim of this study was to determine the efficacy, safety, and pharmacokinetics of ibrutinib in Chinese patients with relapsed or refractory (r/r) WM. Methods: This was an open-label, single-arm, multicenter phase 4 study conducted across five sites in China. Enrolled patients with clinicopathological confirmed WM received ibrutinib 420 mg once daily orally until disease progression or unacceptable toxicity. The primary endpoint was major response rate (MRR, partial response [PR], or better) according to the modified consensus criteria from the Sixth International Workshop on WM. Results: Seventeen patients were enrolled; at data cutoff (March 19, 2022), MRR was 64.7% (90% confidence interval [CI] 42.0–83.4) and overall response rate was 100% (90% CI 83.8–100.0). One (5.9%) patient achieved very good PR, 10 (58.8%) achieved PR, and six (35.3%) achieved minor response. The median duration of response (PR or better) was 14.8 months (95% CI 10.8–not estimable [NE]). Median progression-free survival was 18.4 months (95% CI 12.9–NE). All patients experienced at least one treatment-emergent adverse event (TEAE) related to the study drug, and grade ≥ 3 TEAEs were reported in 13 (76.5%) patients. There were no TEAEs leading to dose reduction or death. The median model estimated maximum plasma concentration and area under the plasma concentration–time curve during 24 h after dosing at steady state were 40.5 ng/mL and 204 ng·h/mL, respectively. Conclusions: Ibrutinib demonstrated durable responses in Chinese patients with r/r WM. Treatment was well tolerated with no new safety signals compared with the pivotal global studies. Ibrutinib exposure was also comparable between Chinese and non-Chinese patients. Trial Registration: ClinicalTrials.gov identifier NCT04042376. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Clinical and clonal characteristics of monoclonal immunoglobulin M‐associated type I cryoglobulinaemia.
- Author
-
Khwaja, Jahanzaib, Vos, Josephine M. I., Pluimers, Tessa E., Japzon, Nicole, Patel, Aisha, Salter, Simon, Kwakernaak, Arjan J., Gupta, Rajeev, Rismani, Ali, Kyriakou, Charalampia, Wechalekar, Ashutosh D., and D'Sa, Shirley
- Subjects
- *
NON-Hodgkin's lymphoma , *WALDENSTROM'S macroglobulinemia , *HOCKEY , *PERIPHERAL neuropathy , *OVERALL survival , *MYELOID differentiation factor 88 - Abstract
Summary: Monoclonal immunoglobulin M‐associated type I cryoglobulinaemia is poorly characterised. We screened 534 patients with monoclonal IgM disorders over a 9‐year period and identified 134 patients with IgM type I cryoglobulins. Of these, 76% had Waldenström macroglobulinaemia (WM), 5% had other non‐Hodgkin lymphoma (NHL) and 19% had IgM monoclonal gammopathy of undetermined significance (MGUS). Clinically relevant IgM‐associated disorders (including cold agglutinin disease [CAD], anti‐MAG antibodies, amyloidosis and Schnitzler syndrome) coexisted in 31%, more frequently in MGUS versus WM/NHL (72% vs. 22%/29%, p < 0.001). The majority of those with cryoglobulins and coexistent CAD/syndrome had the molecular characteristics of a CAD clone (wild‐type MYD88 in 80%). A half of all patients had active manifestations at cryoglobulin detection: vasomotor (22%), cutaneous (16%), peripheral neuropathy (22%) and hyperviscosity (9%). 16/134 required treatment for cryoglobulin‐related symptoms alone at a median of 38 days (range: 6–239) from cryoglobulin detection. At a median follow‐up of 3 years (range: 0–10), 3‐year cryoglobulinaemia‐treatment‐free survival was 77% (95% CI: 68%–84%). Age was the only predictor of overall survival. Predictors of cryoglobulinaemia‐related treatment/death were hyperviscosity (HR: 73.01; 95% CI: 15.62–341.36, p < 0.0001) and cutaneous involvement (HR: 2.95; 95% CI: 1.13–7.71, p = 0.028). Type I IgM cryoglobulinaemia is more prevalent than previously described in IgM gammopathy and should be actively sought. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Long-term Survival in a Patient With Transformation of Waldenström's Macroglobulinemia into DLBCL.
- Author
-
SOLIA, EIRINI, NTANASIS-STATHOPOULOS, IOANNIS, KASTRITIS, EFSTATHIOS, TERPOS, EVANGELOS, DIMOPOULOS, MELETIOS A., and GAVRIATOPOULOU, MARIA
- Subjects
WALDENSTROM'S macroglobulinemia ,DIFFUSE large B-cell lymphomas ,IMMUNOGLOBULIN M ,LACTATE dehydrogenase - Abstract
Background/Aim: Waldenström's macroglobulinemia (WM) is a rare slow-growing B-cell lymphoma that is characterized by lymphoplasmacytic bone marrow infiltration and the production of monoclonal immunoglobulin M (IgM) paraprotein. In 5-10% of patients, WM undergoes transformation into diffuse large B-cell lymphoma (DLBCL), which is more aggressive, with poor prognosis and a low survival rate. Case Report: A 69-year-old woman was diagnosed with WM in 2009. She received six cycles of chemoimmunotherapy and a remarkable remission was achieved. However, in 2013 the disease transformed into DLBCL. The patient received chemotherapy and after the completion of the first cycle of therapy, the disease was significantly minimized. At the end of the therapy, there was no evidence of disease, and the patient remains disease-free. The cytogenetic profile of the patient did not reveal expression of BCL2 apoptosis regulator, BCL6 transcription repressor, Epstein--Barr virus small RNA, syndecan 1 nor cyclin D1. According to a staging system based on the platelet count, lactate dehydrogenase and previous treatment for WM, the described patient was classified as being at intermediate risk with an expected 2-year survival probability of 47% after WM transformation into DLBCL. However, the patient unexpectedly exceeded these prognostic indications. Conclusion: The findings for this patient are of great interest compared with the existing literature which suggests that the survival and prognosis for patients with transformed DLBCL are not favorable. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Effective treatment of pleural effusion in chronic lymphocytic leukemia with acalabrutinib: a case report.
- Author
-
Kurosawa, Shuhei, Yokota, Takako, Takada, Yusuke, Okubo, So, Masuda, Moe, Nakayama, Hitomi, Sakurai, Aki, Ito, Chisako, Aisa, Yoshinobu, and Nakazato, Tomonori
- Subjects
- *
CHRONIC lymphocytic leukemia , *PLEURAL effusions , *BRUTON tyrosine kinase , *WALDENSTROM'S macroglobulinemia , *MEDICAL personnel , *CHRONIC leukemia , *EXTRAMEDULLARY diseases - Abstract
This letter, published in the Annals of Hematology, reports on a case of an elderly patient with chronic lymphocytic leukemia (CLL) and pleural effusion who was successfully treated with acalabrutinib, a second-generation Bruton's tyrosine kinase (BTK) inhibitor. The patient had no significant medical history and was initially monitored without treatment. However, when she developed exertional dyspnea and pleural effusion, acalabrutinib was initiated, leading to gradual improvement and eventual resolution of the effusion. This case highlights the potential efficacy of acalabrutinib in treating CLL with pleural effusion and suggests that BTK inhibitors may have a role in managing extramedullary lesions in CLL. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
34. Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
- Author
-
Pharmacyclics LLC. and Steven Treon, MD, PhD, Steven P. Treon, MD, PhD
- Published
- 2022
35. Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Published
- 2022
36. A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
- Published
- 2022
37. Broadening the horizon: potential applications of CAR-T cells beyond current indications.
- Author
-
Karsten, Hendrik, Matrisch, Ludwig, Cichutek, Sophia, Fiedler, Walter, Alsdorf, Winfried, and Block, Andreas
- Subjects
HAIRY cell leukemia ,CUTANEOUS T-cell lymphoma ,DIFFUSE large B-cell lymphomas ,MULTIPLE myeloma ,HEMATOLOGIC malignancies ,MANTLE cell lymphoma - Abstract
Engineering immune cells to treat hematological malignancies has been a major focus of research since the first resounding successes of CAR-T-cell therapies in BALL. Several diseases can now be treated in highly therapy-refractory or relapsed conditions. Currently, a number of CD19- or BCMA-specific CAR-T-cell therapies are approved for acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma (MM), and follicular lymphoma (FL). The implementation of these therapies has significantly improved patient outcome and survival even in cases with previously very poor prognosis. In this comprehensive review, we present the current state of research, recent innovations, and the applications of CAR-T-cell therapy in a selected group of hematologic malignancies. We focus on B- and T-cell malignancies, including the entities of cutaneous and peripheral T-cell lymphoma (T-ALL, PTCL, CTCL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), classical Hodgkin-Lymphoma (HL), Burkitt-Lymphoma (BL), hairy cell leukemia (HCL), and Waldenström’s macroglobulinemia (WM). While these diseases are highly heterogenous, we highlight several similarly used approaches (combination with established therapeutics, target depletion on healthy cells), targets used in multiple diseases (CD30, CD38, TRBC1/2), and unique features that require individualized approaches. Furthermore, we focus on current limitations of CAR-T-cell therapy in individual diseases and entities such as immunocompromising tumor microenvironment (TME), risk of on-target-off-tumor effects, and differences in the occurrence of adverse events. Finally, we present an outlook into novel innovations in CAR-T-cell engineering like the use of artificial intelligence and the future role of CAR-T cells in therapy regimens in everyday clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. Lymphoplasmacytic lymphoma presenting cold agglutinin syndrome: Clonal expansion of KMT2D and IGHV4‐34 mutations after COVID‐19.
- Author
-
Hayashi, Kiyohito, Koyama, Daisuke, Sato, Yuki, Fukatsu, Masahiko, and Ikezoe, Takayuki
- Subjects
- *
BONE marrow cells , *SCOTOMA , *COVID-19 , *AGGLUTINATION , *ERYTHROCYTES , *WALDENSTROM'S macroglobulinemia , *SYNDROMES - Abstract
This article discusses a case of lymphoplasmacytic lymphoma (LPL) presenting as cold agglutinin syndrome (CAS) in a patient who had previously been infected with COVID-19. CAS is an autoimmune condition characterized by the presence of cold agglutinins, which are antibodies that cause the clumping of red blood cells. The patient in this case had elevated levels of IgM and exhibited symptoms such as visual field defects and haemolytic attacks. Whole-exome sequencing revealed the presence of a KMT2D mutation in the patient's bone marrow cells after COVID-19, suggesting clonal expansion of LPL cells. The study highlights the potential association between CAS and COVID-19, as well as the importance of considering molecular diagnosis and clonal evolution in the treatment of LPL with CAS. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
39. Experience with pre‐diluted plasma exchange therapy for hyperviscosity syndrome.
- Author
-
Igarashi, Shigeyuki, Kamikawa, Yasutaka, Ono, Syuji, Maekawa, Gakuya, Kishigami, Hiroyuki, Kawamura, Kazuki, Oonogi, Takumi, and Nagano, Toshihiko
- Subjects
MEMBRANE separation ,TERMINATION of treatment ,MULTIPLE myeloma ,SYNDROMES ,BLOOD coagulation ,WALDENSTROM'S macroglobulinemia - Abstract
Introduction: Plasma exchange therapy (PE) is useful for patients with primary macroglobulinemia and multiple myeloma who present with hyperviscosity syndrome. However, hyperviscous blood may coagulate in the circuit during treatment, and in that case necessitate discontinuation of the treatment. This time, we report that we were able to prevent coagulation in the circuit by adding some ideas during the membrane separation method. Methods: Physiological saline is injected in front of the plasma separation membrane to pre‐dilute the blood, followed by filtration through the plasma separation membrane. Results: As a result of pre‐diluting with physiological saline to reduce the viscosity entering the separation membrane, it was possible to process the planned target amount. Conclusion: In patients with hyperviscosity syndrome who showed intracircuit coagulation during plasma exchange therapy, devising a predilution method should be considered as one of the ways to continue treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Waldenström's Macroglobulinemia and Cryoglobulinemic Glomerulonephritis: An Unusual Case of Monoclonal Gammopathy of Renal Significance.
- Author
-
De La Flor, José C., Sulca, Jesús de María, Rodríguez, Pablo, Villa, Daniel, Sandoval, Edna, Zamora, Rocío, Monroy-Condori, Maribel, Lipa, Roxana, Perez, Henry, and Cieza, Michael
- Subjects
GLOMERULONEPHRITIS ,BLOOD protein electrophoresis ,MONOCLONAL gammopathies ,ACUTE kidney failure ,NEEDLE biopsy ,NEPHRITIS - Abstract
Cryoglobulins are immunoglobulins that precipitate at temperatures below 37 °C and dissolve upon reheating. They can induce small-vessel vasculitis with renal involvement. Cryoglobulinemic glomerulonephritis is a rare manifestation that occurs in patients with monoclonal gammopathy, specifically Waldenström's macroglobulinemia. We present the case of a 52-year-old patient with a history of cutaneous vasculitis and hypothyroidism, who presented with generalized edema, moderate anemia, hypercholesterolemia, nephrotic range proteinuria of 12.69 g/day, microhematuria, arterial hypertension, and hypocomplementemia via the classical pathway, without acute kidney injury and with negative serological studies and positive cryoglobulins in the second determination. Serum and urine protein electrophoresis and immunofixation studies showed a monoclonal band of IgM and kappa light chain. Renal biopsy was consistent with cryoglobulinemic glomerulonephritis. In the context of dysproteinemia and cryoglobulinemic glomerulonephritis, bone-marrow aspiration and biopsy were performed, leading to the diagnosis of Waldenström's macroglobulinemia. Monoclonal gammopathies have been described in association with type I cryoglobulinemias. This described association is uncommon, which is why we present this case, along with a review of the literature. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. A Rare Case of Subcutaneous Amyloidoma Associated with Localized Lymphoplasmacytic Lymphoma: Diagnostic Challenges and Treatment Considerations.
- Author
-
Vivian, Lisa Francesca, Marcelis, Lukas, Leoni, Eleonora, De Bruecker, Yves, Maes, Helena, Pierré, Erwin, Ballaux, Florence M., and Tousseyn, Thomas
- Subjects
- *
WALDENSTROM'S macroglobulinemia , *MUCOSA-associated lymphoid tissue lymphoma , *CARDIAC amyloidosis , *BLOOD diseases , *LITERATURE reviews , *CEREBRAL amyloid angiopathy , *THERAPEUTICS - Abstract
Objective: Rare disease Background: AL amyloidomas are solitary, localized, tumor-like deposits of immunoglobulin light-chain-derived amyloid fi- brils in the absence of systemic amyloidosis. A rare entity, they have been described in various anatomical sites, typically in spatial association with a sparse lymphoplasmacytic infiltrate, ultimately corresponding to a clonal, malignant, lymphomatous disorder accounting for the amyloidogenic activity. Most frequently, the amyloidoma-associated hematological disorder corresponds to either a solitary plasmacytoma or an extranodal marginal zone lymphoma of MALT. Much rarer is the association with lymphoplasmacytic lymphoma, which by itself is usually a bone marrow-bound disorder with systemic burden. The almost anecdotic combination of an amyloidoma and a localized lymphoplasmacytic lymphoma deserves attention, as it entails a thorough diagnostic workup to exclude systemic involvement and a proportionate therapeutic approach to avoid overtreatment. A review of the literature provides an insight on pathogenesis and prognosis, and can assist both pathologists and clinicians in establishing optimal patient management strategies. Case Report: We herein report the incidental finding of a subcutaneous amyloidoma caused by a spatially related, similarly localized lymphoplasmacytic lymphoma diagnosed in a 54-year-old female patient with no other disease localizations and a complete remission following 2 subsequent surgical excisions. Conclusions: Whatever the specific combination of an amyloidoma and the related hematological neoplasm, a multidisciplinary collaboration and a comprehensive clinical-pathological staging are warranted to exclude systemic involvement and identify patients with localized diseases who would benefit from local active treatment and close follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
42. A 35-year-old Male with Waldenstrom Macroglobulinemia.
- Author
-
HOSSAIN, T., DEWAN, A., RAHMAN, A., DAS, N. R., UDDIN, M. N. N., CHOWDHURY, M. M. H., and ISLAM, M. R.
- Subjects
- *
FATIGUE (Physiology) , *WEIGHT loss , *OLDER people , *NON-Hodgkin's lymphoma , *BONE marrow , *WALDENSTROM'S macroglobulinemia , *MONOCLONAL gammopathies - Abstract
Waldenstrom macroglobulinemia is one type of non-Hodgkin lymphoma that presents with a wide range of clinical features mainly due to secretion of the IgM paraprotein and infiltration of lymphoplasmacytic cells. Patients with Waldenstrom macroglobulinemia may experience fatigue, unexplained weight loss, enlarged lymph nodes, abdominal swelling, weakness, nose bleeding, blurring of vision etc. Waldenstrom macroglobulinemia is a disease of elderly individuals. The median age at diagnosis is 65 years, with a slight male predominance. We reported a case of a 35-year-old male who presented with fever, abdominal pain, loose motion and epistaxis. Examination revealed cervical and inguinal lymphadenopathy with hepatosplenomegaly. Investigation revealed diffuse lymphocyte infiltration on bone marrow study. Protein electrophoresis showed monoclonal gammopathy with high serum IgM level. On the basis of clinical features and investigation reports finally we diagnosed that, this was a rare case of Waldenstrom macroglobulinemia in a young patient. The patient was transfused 5 units of whole blood and was treated following standard treatment protocol with dexamethasone, Bortezomib and G-CSF. Unfortunately, patient died 3 weeks after initiation of treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
43. An unusual presentation of immunoglobulin A gammopathy in a patient with Schnitzler's syndrome.
- Author
-
Kaganov, Elizabeth, Jhaveri, Divita, Peters, Peter, and IJdo, Jacob W.
- Subjects
- *
IMMUNOGLOBULIN M , *INTERLEUKIN-1 receptors , *SYNDROMES , *IMMUNOGLOBULIN G , *ANAKINRA , *WALDENSTROM'S macroglobulinemia - Abstract
This case summarizes a 69‐year‐old woman who presented with a history of recurrent fevers, widespread urticarial rash and generalized myalgias for several years with an eventual diagnosis of Schnitzler's syndrome. This is a rare autoinflammatory condition which typically involves a chronic urticarial rash, monoclonal immunoglobulin M (IgM) or IgG gammopathy. Rapid improvement in above symptoms were noted with anakinra, an interleukin‐1 receptor antagonist. We report an unusual case of a 69‐year‐old woman who presented with an isolated IgA monoclonal gammopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
44. Extramedullary hematopoietic pleural effusion in Waldenström's macroglobulinemia
- Author
-
Kenichi Ito, Kunihiko Harada, Yoshihito Uchino, Kazuhiko Hirano, and Naohiro Sekiguchi
- Subjects
6q deletion ,extramedullary hematopoiesis ,extramedullary hematopoietic effusion ,Waldenström's macroglobulinemia ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract Extramedullary hematopoietic effusion (EHE) is one of the extremely rare phenomena associated with extramedullary hematopoiesis, which is caused by serous effusions, including pleural effusion, and may be related to hematologic disorders and neoplasms. Herein, we present the case of an 81‐year‐old man with EHE accompanying Waldenström's macroglobulinemia (WM). The patient complained of anemia and dyspnea. The chest X‐ray and computed tomography showed a massive left pleural effusion, and the aspirates revealed infiltration of the immature myeloid cells and megakaryocytes, in addition to the lymphoma cells. To our knowledge, this is the first report of EHE in WM.
- Published
- 2023
- Full Text
- View/download PDF
45. Intraparenchymal Lung Abscess Complicating a Primary COVID-19 Infection in a Patient with Waldenström’s Macroglobulinemia: A Case Report
- Author
-
Panagiotis F. Mavroudis, Lemonia Velentza, Panagiotis G. Sfyridis, Styliani Papantoniou, Georgios Kranidiotis, Efthymia Giannitsioti, Alexandra Stamati, Dimitrios Schizas, Styliani Gerakari, and Emmanouil I. Kapetanakis
- Subjects
COVID-19 ,SARS-CoV-2 ,pandemic ,lung abscess ,cavitating lung lesion ,Waldenström’s macroglobulinemia ,Other systems of medicine ,RZ201-999 - Abstract
Intraparenchymal lung abscess development associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a rare complication, with only half a dozen primary cases having been reported in the literature. We present the case of a patient with Waldenström’s macroglobulinemia who developed a lung abscess subsequent to a primary SARS-CoV-2 infection. We present a 63-year-old male patient with SARS-CoV-2 infection and a history of Waldenström’s macroglobulinemia who developed a cavitating intraparenchymal lung abscess with an air-fluid level in his right lower lobe two weeks following admission to hospital. The patient became septic and developed acute respiratory failure requiring mechanical ventilation and intensive care. He was managed with broad-spectrum antibiotic therapy and aspiration drainage, but unfortunately due to his severe clinical condition died 20 days after his initial admission. The development of a lung abscess in patients with COVID-19, although rare, can be quite compromising and even prove fatal, especially in immunocompromised patients. Clinicians should be aware of this potential complication.
- Published
- 2023
- Full Text
- View/download PDF
46. Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
- Published
- 2022
47. Hematologic secondary malignancies among 102 Chinese patients with Waldenstrom’s macroglobulinemia: a single-center case experience and literature review
- Author
-
Lingling Wang, Conglin Xi, Yongfen Huang, Hao Xu, Yuqing Miao, and Yuexin Cheng
- Subjects
Waldenstrom’s macroglobulinemia ,secondary malignancies ,B cell ,incidence ,prognosis ,Chinese ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Waldenstrom’s macroglobulinemia (WM) is a rare and indolent B-cell lymphoma. To investigate the type and survival of hematologic secondary malignancies (SMs) in Chinese patients with WM, we retrospectively reviewed the characteristics of 102 patients with WM from February 2002 to May 2023 in our center. Four men and two women were diagnosed with hematologic SMs. Of the six patients with hematologic SMs, one was diagnosed with acute myeloid leukemia (AML), one with multiple myeloma (MM), one with myelodysplastic syndrome (MDS), one with B-cell acute lymphoblastic leukemia (B-ALL), and two with diffuse large B-cell lymphoma (DLBCL). The median age was 65.5 years (56–74 years). The median interval time between diagnosis of WM and hematologic SMs was 39.5 months (10–117 months). Among those with WM with hematologic SMs, five died and one survived. Overall survival (OS) was just 33 months (12–119 months) on median. A total of 32 patients died and 64 survived in the group of WM without hematologic SMs, and the median OS was 82 months (3–250 months). This is the first study in the Chinese population on hematologic SMs in WM. The purpose of this study was to investigate the prognosis of hematologic SMs in WM in the Chinese population, as well as to compare the population’s characteristics to those of other centers. We investigated the underlying causes further and presented a research strategy for our forthcoming investigation. We intend to investigate risk factors for SMs as well as more accessible screening methods.
- Published
- 2023
- Full Text
- View/download PDF
48. A Case of Lymphoma with Multiple Identities.
- Author
-
Asri, Alia Suzana, Yousuf, Rabeya, Yahaya, Azyani, Zainal, Isa Izzaki, Tumian, Nor Rafeah, Nasuruddin, Dian Nasriana, Yusof, Nurasyikin, and Aziz, Suria Abdul
- Subjects
- *
DIFFUSE large B-cell lymphomas , *IMMUNOGLOBULIN light chains , *WALDENSTROM'S macroglobulinemia , *POSITRON emission tomography computed tomography , *LYMPHOMAS , *FOLLICULAR lymphoma - Abstract
Discordant lymphoma (DL) is the coexistence of two or more distinct subtypes in separate anatomic sites. There are limited reports on DL cases especially involving more than two subtypes in more than two sites. We report a 76-year-old man who presented with constitutional symptoms, flank mass and painless lymphadenopathies for six months. Laboratory tests revealed moderate anaemia, markedly elevated serum IgM (13400 mg/dL), IgM Lambda paraproteinemia and Lambda light chain paraproteinuria with unmeasurable serum lactate dehydrogenase due to hyperviscous sample. CT scan showed multiple subcutaneous masses over chest wall and retroperitoneum, with lytic bone lesions, and hepatosplenomegaly. Further biopsy findings with morphological, immunohistochemical and molecular analysis of the tissue sections revealed diffuse large B-Cell lymphoma in the chest wall mass, follicular lymphoma in the inguinal lymph node and lymphoplasmacytic lymphoma in the bone marrow. This case highlights the rare DL. The importance of histopathological evaluation of lymphoma despite the availability of PET-CT scans for disease staging is undeniable. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
49. The Histopathology of Cold Agglutinin Disease–Associated B-Cell Lymphoproliferative Disease.
- Author
-
Guenther, Angela, Tierens, Anne, Malecka, Agnieszka, and Delabie, Jan
- Subjects
- *
B cells , *LYMPHOPROLIFERATIVE disorders , *MUCOSA-associated lymphoid tissue lymphoma , *BONE marrow diseases , *AUTOIMMUNE hemolytic anemia , *WALDENSTROM'S macroglobulinemia - Abstract
Objectives Primary cold agglutinin disease is a type of autoimmune hemolytic anemia caused by circulating antibodies against I antigen, a carbohydrate expressed on most cells, including red blood cells. The underlying disease has been characterized in recent years as a distinct B-cell lymphoproliferative disease of the bone marrow, occurring mostly in the elderly. The disease has been now been included as a separate entity in the most recent classifications of mature B-cell neoplasms. Methods A review of the characteristics of cold agglutinin disease is provided, with an emphasis on the pathology features. Results A detailed description of the histopathology, immunophenotype, and genetics of cold agglutinin disease is provided and compared to other B-cell lymphoproliferative diseases in the bone marrow with similar features. Conclusions Recognition of the pathology features of cold agglutinin disease allows to distinguish it from other diseases, especially lymphoplasmacytic lymphoma and marginal zone lymphoma. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
50. Waldenström's macroglobulinemia with necrotic extremities: A case with challenging diagnosis.
- Author
-
Nekooghadam, Seyyed Mojtaba, Ghadirzadeh, Erfan, Lapevandani, Mahsa Mohammadi, Ghorbani, Parastoo, Yazdi, Yeganeh Ghalichehbaf, Shafiei, Sasan, Rakhshan, Azadeh, Paraandavaji, Elham, and Charkazi, Elham
- Subjects
- *
BONE marrow cells , *WALDENSTROM'S macroglobulinemia , *IMMUNOGLOBULIN M , *PLASMA cells , *DIAGNOSIS , *PHYSICIANS - Abstract
Key Clinical Message: Waldenström's macroglobulinemia may begin with constitutional symptoms that are common in primary care settings and it is crucial for physicians to be aware of the potential complications of hyperviscosity syndrome and to employ the appropriate diagnostic methods in order to achieve better outcomes. Waldenström's macroglobulinemia (WM) refers to a type of lymphoplasmacytic lymphoma distinguished by the hyperproliferation of plasma cells, lymphocytes, and plasmacytoid lymphocytes. The disease is primarily diagnosed by increased monoclonal immunoglobulin M (IgM) levels and lymphoplasmacytic cell infiltration into the bone marrow. Individuals exhibit a high risk for hyperviscosity syndrome (HVS) as immunoglobulin levels increase. In addition to constitutional symptoms (fever, night sweats, and unintentional weight loss), clinical findings such as cytopenia, hepatosplenomegaly, and lymphadenopathy, this condition may cause hyperviscosity‐related organ failures. Here we discuss a patient with WM who presented with neurological complaints and blurry vision and developed necrosis at distal portions of his body during the 6‐month course of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.